SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-304559
Filing Date
2020-11-27
Accepted
2020-11-27 16:06:01
Documents
14
Period of Report
2020-11-27
Items
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d97249d8k.htm   iXBRL 8-K 30074
2 EX-99.1 d97249dex991.htm EX-99.1 7416
6 GRAPHIC g97249g1125202756419.jpg GRAPHIC 3429
  Complete submission text file 0001193125-20-304559.txt   169528

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA clvs-20201127.xsd EX-101.SCH 3088
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE clvs-20201127_lab.xml EX-101.LAB 18139
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE clvs-20201127_pre.xml EX-101.PRE 11420
7 EXTRACTED XBRL INSTANCE DOCUMENT d97249d8k_htm.xml XML 3356
Mailing Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301
Business Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301 (303) 625-5000
Clovis Oncology, Inc. (Filer) CIK: 0001466301 (see all company filings)

IRS No.: 900475355 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35347 | Film No.: 201355372
SIC: 2834 Pharmaceutical Preparations